Romo-Sánchez MG, Rodríguez-Hernández JJ, Villalobos-Pérez MA

Language: Spanish
References: 20
Page: 257-269
PDF size: 478.15 Kb.

ABSTRACT

Background: Malignant mesothelioma is an infrequent neoplasm but is increasing in incidence because of past industrial practices. In Mexico it causes approximately 100 deaths annually but it is predicted a rise of mortality. The prognostic is poor with a median survival in the order of 10 months or less.
Objective: To determine the prognostic utility of Bcl-2, p27, p53 and MIB-1 and their relation with the recognized risk factors of pleural mesothelioma.
Patients and method: A cohort and ambispective study was done with 91 patients with diagnosis of malignant mesothelioma in surgical biopsies of pathology service of National Institute of Respiratory Diseases of Mexico from January 1995 to June 2003. Reactivity indexes in biopsy were obtained with morphologic and phenotypic diagnosis using an image analyzer with AxioVision system.
Results: expression of antibodies bcl 2, p27, MIB-1 and p53 was bcl 2+ in 2%, p27+ in 61.2%, MIB-1+ in 70.5% and p53+ in 42.1%.
Conclusions: In this study it was determined that the risk attributed to the age is because of the loss of cell protection mechanisms; the loss of tumor suppression with increase of age has not been previously described. The survival period also showed statistical significance with the increase of tumor cell proliferation as the disease progresses. The Cox survival analysis didn´t show statistical significance compared to some clinical variables recognized as risk factor. This study shows that the expression of p27, p53 and MIB-1 is associated with the prognosis of patients with malignant mesotheliomas.

REFERENCES

1. Gottehrer A, Taryle DA, Reed CE, Sahn SA. Pleural fluid analysis in malignant mesothelioma. Chest 1991;100:1003- 1006.

2. Beer TW, Shepherd P, Pullinger NC. p27 immunostaining is related to prognosis in malignant mesothelioma. Histopathology 2001;38:535-541.

3. Jarvinen K, Soini Y, Kahlos K, Kinnula VL. Overexpression of g-glutamylcysteine synthetase in human malignant mesothelioma. Human Pathol 2002;33:748-755.

4. Chailleux E, Dabouis G, Pioche D, Lajartre M, et al. Prognostic factors in diffuse malignant mesothelioma. Chest 1988;93:159-162.

5. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002;29:2-17.

6. Steele JPC. Prognostic factors in mesothelioma. Semin Oncol 2002;29:36-40.

7. Gottehrer A, Taryle DA, Reed CE, Sahn SA. Pleural fluid analysis in malignant mesothelioma. Chest 1991;100:1003- 1006.

8. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patient with mesothelioma treated between 1984 and 1994 by the cancer and leukemia Group B. Chest 1998;113:723-731.

9. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma. J Clin Oncol 1998;16:145-152.

10. Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORT prognostic scoring systems. Thorax 2000;55:731-735.

11. Kafiri G, Thomas DM, Shepherd NA, Krausz T, et al. p53 expression is common in malignant mesothelioma. Histopathology 1992;21:331-334.

12. Ramael M, Jacobs W, Weyler J, Meerbeeck J, et al. Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA). J Pathology 1994;172:247-253.

13. Beer TW, Buchanan R, Matthews AL, Stradling R, et al. Prognosis in malignant mesothelioma related to MIB-1 proliferation index and histological subtype. Hum Pathol 1998;29:246-251.

14. Jäckel MC, Dorudian MA, Marx D, Brinck U, et al. Spontaneous apoptosis in laryngeal squamous cell carcinoma is independent of bcl-2 and bax protein. Cancer 1999;85:591- 599.

15. Kokawa K, Shikone T, Otani T, Nakano R. Apoptosis and expression of bax and bcl-2 in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Cancer 1999;85:591-599.

16. Soini Y, Kinnula V, Kaarteenaho-Wiik R, Kurttila E, et al. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin Cancer Res 1999;5:3508-3515.

17. Narasimhan SR, Yang L, Gerwin BI, Broaddus VC. Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of bcl-2 and bax. Am J Physiol 1998;275:165- 171.

18. Ordonez NG. Immunohistochemical diagnosis of epitheloid mesotheliomas: a critical review of old markers, new markers. Hum Pathol 2002;33:953-967.

19. Tibor T. The value of cytokeratines 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas. Cancer 2001;92:2727-2732.

20. Liddell FDK, McDonald AD, McDonald JC. The 1891-1920 birth cohort of Quebec chrysotile miners and millers: Development from 1904 and mortality to 1992. Ann Occup Hyg 1997;41:13-36.